Skip to main content

Advertisement

SpringerLink
Log in

Churg-Strauss Syndrome: An Update

  • Vasculitis (Luis R. Espinoza, Section Editor)
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Churg-Strauss syndrome is an uncommon disease of unknown cause described initially by Churg and Strauss in 1951. Even though it was initially thought to be a variant of polyarteritis nodosa, its pathological, clinical, and laboratory features show that it is related to the small vessel vasculitides, and it is now classified as an antineutrophil cytoplasmic antibody–associated vasculitis. The presence of asthma, usually of adult onset, along with other allergic symptoms, peripheral and tissue eosinophilia, is specific to this disease. These features usually help clinicians distinguish it from other types of small vessel vasculitis and should alert clinicians about its presence. Two different clinical subtypes defined by the presence of antineutrophil cytoplasmic antibodies recently have been recognized. Recent advances in the treatment and pathophysiology of Churg-Strauss syndrome are reviewed in this article.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Falk RJ et al. Granulomatosis with polyangiitis (Wegener’s): an alternative name for Wegener’s granulomatosis. Arthritis Rheum. 2011;63(4):863–4.

    Article  PubMed  Google Scholar 

  2. Lie JT. Illustrated histopathologic classification criteria for selected vasculitis syndromes. American College of Rheumatology Subcommittee on Classification of Vasculitis. Arthritis Rheum. 1990;33(8):1074–87.

    Article  PubMed  CAS  Google Scholar 

  3. Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol. 1951;27(2):277–301.

    PubMed  CAS  Google Scholar 

  4. Rose GA, Spencer H. Polyarteritis nodosa. Q J Med. 1957;26(101):43–81.

    PubMed  CAS  Google Scholar 

  5. • Baldini, C., et al., Clinical manifestations and treatment of Churg-Strauss syndrome. Rheum Dis Clin North Am, 2010. 36(3): p. 527–43. This is an excellent recent review of CSS, with emphasis on clinical and therapeutic issues.

    Article  PubMed  Google Scholar 

  6. Kahn JE, Bletry O, Guillevin L. Hypereosinophilic syndromes. Best Pract Res Clin Rheumatol. 2008;22(5):863–82.

    Article  PubMed  CAS  Google Scholar 

  7. Sinico RA, Bottero P. Churg-Strauss angiitis. Best Pract Res Clin Rheumatol. 2009;23(3):355–66.

    Article  PubMed  Google Scholar 

  8. Abril A, Calamia KT, Cohen MD. The Churg Strauss syndrome (allergic granulomatous angiitis): review and update. Semin Arthritis Rheum. 2003;33(2):106–14.

    Article  PubMed  Google Scholar 

  9. Mahr A et al. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener’s granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum. 2004;51(1):92–9.

    Article  PubMed  Google Scholar 

  10. • Bochner, B.S. and G.J. Gleich, What targeting eosinophils has taught us about their role in diseases. J Allergy Clin Immunol, 2010. 126(1): p. 16–25; quiz 26–7. This is a basic review on eosinophils and their role in the pathogenesis of related conditions written in language that should be easy to understand for clinicians with minimal basic science background.

    Article  PubMed  CAS  Google Scholar 

  11. Akuthota P, Wang H, Weller PF. Eosinophils as antigen-presenting cells in allergic upper airway disease. Curr Opin Allergy Clin Immunol. 2010;10(1):14–9.

    Article  PubMed  CAS  Google Scholar 

  12. Kouro T, Takatsu K. IL-5- and eosinophil-mediated inflammation: from discovery to therapy. Int Immunol. 2009;21(12):1303–9.

    Article  PubMed  CAS  Google Scholar 

  13. Weller PF. Human eosinophils. J Allergy Clin Immunol. 1997;100(3):283–7.

    Article  PubMed  CAS  Google Scholar 

  14. Schmitt WH et al. Churg-Strauss syndrome: serum markers of lymphocyte activation and endothelial damage. Arthritis Rheum. 1998;41(3):445–52.

    Article  PubMed  CAS  Google Scholar 

  15. Hellmich B, Csernok E, Gross WL. Proinflammatory cytokines and autoimmunity in Churg-Strauss syndrome. Ann N Y Acad Sci. 2005;1051:121–31.

    Article  PubMed  CAS  Google Scholar 

  16. • Terrier, B., et al., Interleukin-25: a cytokine linking eosinophils and adaptive immunity in Churg-Strauss syndrome. Blood, 2010. 116(22): p. 4523–31. This is a very interesting paper explaining a new potential immunologic mechanism of eosinophil activation in CSS.

    Article  PubMed  CAS  Google Scholar 

  17. Dallos T et al. CCL17/thymus and activation-related chemokine in Churg-Strauss syndrome. Arthritis Rheum. 2010;62(11):3496–503.

    Article  PubMed  CAS  Google Scholar 

  18. Chen M, Kallenberg CG. New advances in the pathogenesis of ANCA-associated vasculitides. Clin Exp Rheumatol. 2009;27(1 Suppl 52):S108–14.

    PubMed  CAS  Google Scholar 

  19. Xiao H et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest. 2002;110(7):955–63.

    PubMed  CAS  Google Scholar 

  20. Sable-Fourtassou R et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med. 2005;143(9):632–8.

    PubMed  Google Scholar 

  21. Sinico RA et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum. 2005;52(9):2926–35.

    Article  PubMed  CAS  Google Scholar 

  22. Keogh KA, Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med. 2003;115(4):284–90.

    Article  PubMed  CAS  Google Scholar 

  23. Kallenberg CG. Churg-Strauss syndrome: just one disease entity? Arthritis Rheum. 2005;52(9):2589–93.

    Article  PubMed  Google Scholar 

  24. Lane SE et al. Are environmental factors important in primary systemic vasculitis? A case-control study. Arthritis Rheum. 2003;48(3):814–23.

    Article  PubMed  Google Scholar 

  25. Cuchacovich R, Justiniano M, Espinoza LR. Churg-Strauss syndrome associated with leukotriene receptor antagonists (LTRA). Clin Rheumatol. 2007;26(10):1769–71.

    Article  PubMed  CAS  Google Scholar 

  26. Wechsler ME et al. Churg-Strauss syndrome in patients treated with omalizumab. Chest. 2009;136(2):507–18.

    Article  PubMed  Google Scholar 

  27. Holle JU, Wieczorek S, Gross WL. Genetic association studies in ANCA-associated vasculitides: what we have learnt so far and what needs to be done in the future. Clin Exp Rheumatol. 2010;28(1 Suppl 57):5–7.

    PubMed  Google Scholar 

  28. Wieczorek S, Holle JU, Epplen JT. Recent progress in the genetics of Wegener’s granulomatosis and Churg-Strauss syndrome. Curr Opin Rheumatol. 2010;22(1):8–14.

    Article  PubMed  CAS  Google Scholar 

  29. Vaglio A et al. HLA-DRB4 as a genetic risk factor for Churg-Strauss syndrome. Arthritis Rheum. 2007;56(9):3159–66.

    Article  PubMed  CAS  Google Scholar 

  30. Wieczorek S et al. Associations of Churg-Strauss syndrome with the HLA-DRB1 locus, and relationship to the genetics of antineutrophil cytoplasmic antibody-associated vasculitides: comment on the article by Vaglio et al. Arthritis Rheum. 2008;58(1):329–30.

    Article  PubMed  CAS  Google Scholar 

  31. Lanham JG et al. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore). 1984;63(2):65–81.

    CAS  Google Scholar 

  32. Lhote F, Guillevin L. Polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome. Clinical aspects and treatment. Rheum Dis Clin North Am. 1995;21(4):911–47.

    PubMed  CAS  Google Scholar 

  33. Papadimitraki ED et al. Ear-nose-throat manifestations of autoimmune rheumatic diseases. Clin Exp Rheumatol. 2004;22(4):485–94.

    PubMed  CAS  Google Scholar 

  34. Chumbley LC, Harrison Jr EG, DeRemee RA. Allergic granulomatosis and angiitis (Churg-Strauss syndrome). Report and analysis of 30 cases. Mayo Clin Proc. 1977;52(8):477–84.

    PubMed  CAS  Google Scholar 

  35. Erzurum SC et al. Pleural effusion in Churg-Strauss syndrome. Chest. 1989;95(6):1357–9.

    Article  PubMed  CAS  Google Scholar 

  36. Masi AT et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33(8):1094–100.

    Article  PubMed  CAS  Google Scholar 

  37. Guillevin L et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore). 1999;78(1):26–37.

    Article  CAS  Google Scholar 

  38. Davis MD et al. Cutaneous manifestations of Churg-Strauss syndrome: a clinicopathologic correlation. J Am Acad Dermatol. 1997;37(2 Pt 1):199–203.

    Article  PubMed  CAS  Google Scholar 

  39. Rashtak S, Pittelkow MR. Skin involvement in systemic autoimmune diseases. Curr Dir Autoimmun. 2008;10:344–58.

    Article  PubMed  CAS  Google Scholar 

  40. Finan MC, Winkelmann RK. The cutaneous extravascular necrotizing granuloma (Churg-Strauss granuloma) and systemic disease: a review of 27 cases. Medicine (Baltimore). 1983;62(3):142–58.

    CAS  Google Scholar 

  41. • Dennert, R.M., et al., Cardiac involvement in Churg-Strauss syndrome. Arthritis Rheum, 2010. 62(2): p. 627–34. This article is an excellent review of cardiac issues in CSS, the main cause of mortality in these patients. Thus, this is something of which clinicians should be aware.

    PubMed  Google Scholar 

  42. Neumann T et al. Cardiac involvement in Churg-Strauss syndrome: impact of endomyocarditis. Medicine (Baltimore). 2009;88(4):236–43.

    Article  Google Scholar 

  43. Pagnoux C et al. Presentation and outcome of gastrointestinal involvement in systemic necrotizing vasculitides: analysis of 62 patients with polyarteritis nodosa, microscopic polyangiitis, Wegener granulomatosis, Churg-Strauss syndrome, or rheumatoid arthritis-associated vasculitis. Medicine (Baltimore). 2005;84(2):115–28.

    Article  Google Scholar 

  44. Sharma MC, Safaya R, Sidhu BS. Perforation of small intestine caused by Churg-Strauss syndrome. J Clin Gastroenterol. 1996;23(3):232–5.

    Article  PubMed  CAS  Google Scholar 

  45. Sinico RA et al. Renal involvement in Churg-Strauss syndrome. Am J Kidney Dis. 2006;47(5):770–9.

    Article  PubMed  Google Scholar 

  46. Hall FC, Walport MJ. Hypereosinophilic syndromes: association with vasculitis, fibrosis and autoimmunity. Clin Exp Allergy. 1993;23(7):542–7.

    Article  PubMed  CAS  Google Scholar 

  47. • Pagnoux, C. and L. Guillevin, Churg-Strauss syndrome: evidence for disease subtypes? Curr Opin Rheumatol, 2010. 22(1): p. 21–8. This is another excellent clinical review from the French Vasculitis Group, probably the group with the most cumulative experience in CSS and vasculitis in general. This touches on the provocative subject of two different clinical subtypes of this condition.

    Article  PubMed  Google Scholar 

  48. Mukhtyar C et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism Systemic Vasculitis Task Force. Ann Rheum Dis. 2008;67(7):1004–10.

    Article  PubMed  CAS  Google Scholar 

  49. Ribi C et al. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum. 2008;58(2):586–94.

    Article  PubMed  CAS  Google Scholar 

  50. Tatsis E, Schnabel A, Gross WL. Interferon-alpha treatment of four patients with the Churg-Strauss syndrome. Ann Intern Med. 1998;129(5):370–4.

    PubMed  CAS  Google Scholar 

  51. •• Stone, J.H., et al., Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med, 2010. 363(3): p. 221–32. This was a landmark study on rituximab for ANCA-associated vasculits, which is becoming an extremely important therapeutic tool in this group of diseases.

    Article  PubMed  CAS  Google Scholar 

  52. Kim S et al. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol. 2010;125(6):1336–43.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Mayo College of Medicine, Mayo Clinic Florida, 4500 San Pablo Road, Jacksonville, FL, 32224, USA

    Andy Abril

Authors
  1. Andy Abril
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andy Abril.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Abril, A. Churg-Strauss Syndrome: An Update. Curr Rheumatol Rep 13, 489–495 (2011). https://doi.org/10.1007/s11926-011-0205-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-011-0205-7

Keywords

Search

Navigation